July 11, interim report
April – June 2024
Alligator will host a conference call on Thursday, July 11, at 4:15 p.m. CEST/ 10:15 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt, CFO Marie Svensson and CMO Sumeet Ambarkhane will present and comment on the Q2 interim report, which will be followed by a Q&A session. The call will be held in English, and can be accessed through Alligator’s channels on YouTube.
LATEST NEWS
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024
Lund, Sweden and Seattle, Washington, September 13, 2024 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) …
Alligator Bioscience AB reports financial results for H1 2024 and Q2 2024 and provides a business update
Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase …
Alligator Bioscience Announces Completion of Enrollment in Mitazalimab OPTIMIZE-1 Study
Recruitment completed for the additional cohort with 450 µg/kg of mitazalimab in combination with mFOLFIRINOX as requested by FDA ahea …